Spain's Almirall and Proteros of Germany have linked up to develop a treatment in the field of inflammatory diseases, according to PharmaTimes.

Under the terms of the agreement, financial details for which have not been disclosed, Proteros will apply its protein structure-based drug discovery platform to identify small molecule inhibitors against a target selected by Almirall. Jorge Beleta, director of discovery, strategy and alliances at the Barcelona-based firm, said “we have worked with and been impressed by Proteros for many years on our structural biology and compound-profiling projects,” adding that "the broadening of our relationship to fully-integrated projects" is "an exciting next step.”

Proteros, a privately-held company based in Martinsried, provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.